SEC Form 4 · accession 0001209191-16-089483
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul L Berns
Officer — President and CEO · Director
Period of report
Jan 4, 2016
Accepted (ET)
Jan 5, 2016 · 9:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 4, 2016 | S | 80 | $110.97 | D | 254,680 | D | |
| Common StockF3 | Jan 4, 2016 | S | 2,220 | $112.3332 | D | 252,460 | D | |
| Common StockF4 | Jan 4, 2016 | S | 233 | $112.9815 | D | 252,227 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person to cover taxes associated with the vesting of restricted stock units.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.86 to $111.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.89 to $112.86, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.90 to $113.08, inclusive.